Chardan Capital Predicts Immunic FY2025 Earnings

Immunic, Inc. (NASDAQ:IMUX) – Research analysts at Chardan Capital issued their FY2025 EPS estimates for shares of Immunic in a research report issued to clients and investors on Wednesday, November 19th. Chardan Capital analyst K. Nakae expects that the company will earn ($0.65) per share for the year. Chardan Capital has a “Strong-Buy” rating on the stock. The consensus estimate for Immunic’s current full-year earnings is ($0.94) per share. Chardan Capital also issued estimates for Immunic’s FY2026 earnings at ($0.05) EPS.

IMUX has been the topic of a number of other research reports. LADENBURG THALM/SH SH upgraded Immunic to a “strong-buy” rating in a research note on Thursday, October 16th. D. Boral Capital decreased their price objective on shares of Immunic from $10.00 to $8.00 and set a “buy” rating for the company in a report on Thursday, November 13th. HC Wainwright dropped their target price on shares of Immunic from $10.00 to $8.00 and set a “buy” rating on the stock in a research note on Friday, November 14th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Immunic in a research note on Wednesday, October 8th. Finally, Roth Capital assumed coverage on Immunic in a report on Friday, November 7th. They issued a “buy” rating and a $3.00 price target for the company. Two research analysts have rated the stock with a Strong Buy rating, five have given a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Buy” and an average price target of $7.40.

Immunic Stock Performance

Shares of IMUX stock opened at $0.69 on Monday. The stock has a 50 day moving average price of $0.82 and a 200 day moving average price of $0.85. Immunic has a 52-week low of $0.56 and a 52-week high of $1.42. The firm has a market capitalization of $82.56 million, a P/E ratio of -0.73 and a beta of 1.53.

Immunic (NASDAQ:IMUX) last announced its quarterly earnings data on Thursday, November 13th. The company reported ($0.13) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.18) by $0.05.

Institutional Trading of Immunic

Several hedge funds and other institutional investors have recently bought and sold shares of IMUX. Aberdeen Group plc increased its holdings in shares of Immunic by 678.1% in the 2nd quarter. Aberdeen Group plc now owns 8,243,941 shares of the company’s stock valued at $5,750,000 after acquiring an additional 7,184,457 shares during the period. Millennium Management LLC boosted its position in Immunic by 414.5% during the third quarter. Millennium Management LLC now owns 530,470 shares of the company’s stock valued at $468,000 after purchasing an additional 427,361 shares in the last quarter. Focus Partners Wealth grew its stake in Immunic by 19.1% in the first quarter. Focus Partners Wealth now owns 2,583,457 shares of the company’s stock valued at $2,816,000 after purchasing an additional 415,104 shares during the last quarter. Squarepoint Ops LLC bought a new position in Immunic in the third quarter worth about $239,000. Finally, Vanguard Group Inc. lifted its position in shares of Immunic by 5.3% during the third quarter. Vanguard Group Inc. now owns 4,345,105 shares of the company’s stock valued at $3,832,000 after buying an additional 219,957 shares during the last quarter. Institutional investors own 51.82% of the company’s stock.

Immunic Company Profile

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.